Intravenous (IV) Ibuprofen Market Research, 2030

The global intravenous (IV) ibuprofen market size was valued at $5.34 million in 2020, and is projected to reach $15.48 million by 2030, registering a CAGR of 13.4% from 2021 to 2030. The ibuprofen belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs). Ibuprofen acts by non-selective inhibition of cyclooxygenase (COX), which is required for the synthesis of prostaglandins through the arachidonic acid pathway. Thus, ibuprofen blocks the synthesis of prostaglandins (PG), which is responsible for inflammation. The intravenous (IV) ibuprofen alone or with combination with other analgesics is used to treat mild to severe pain. NSAIDs, such as ibuprofen are suitably used for children and adults. However, it is not recommended for geriatric population, as there is a risk of ulcers and bleeding in gastrointestinal track (GIT).

The growth of the global intravenous (IV) ibuprofen market is majorly driven by increase in prevalence of arthritis, cardiovascular diseases, and cancer. The various cancers, such as osteosarcoma (bone cancer), nerve cancer, and leukemia cause mild to severe pain. For instance, as per the American Cancer Society (ACS), about 3,910 new cases of bone cancers were diagnosed in U.S in 2021. Furthermore, high bio-availability and rapid analgesic action of ibuprofen are expected to fuel their adoption during the forecast period. 

Furthermore, increase in prevalence of bone and muscle disorders, such as ankylosing spondylitis (a rare type of arthritis) and rheumatoid arthritis contributes in the growth of the market. For instance, according to a report from the Journal of Rheumatology, titled ‘Prevalence of ankylosing spondylitis in Spain’, about 7.3% population showed positive screening for ankylosing spondylitis in 2020. In addition, rise in number of orthopedic hospitals and diagnostic centers boosts the diagnosis and treatment of diseases. For instance, according to Definitive Healthcare Organization, there were more than 30,500 orthopedic surgeons in the U.S. in 2020. Thus, increase in prevalence of orthopedic surgery and surge the need for intravenous ibuprofen drive the growth of the IV ibuprofen market. 

In addition, increase in prevalence of mucoskeletal diseases contributes in the growth of intravenous (IV) ibuprofen market. According to World Health Organization (WHO), approximately 1.71 billion population suffer from musculoskeletal conditions across the globe. Furthermore, easy availability of ibuprofen as an over the counter medication contributes in growth of market. 

Increase in number of product approvals and government regulations for NSAIDs drug boosts the growth of the intravenous (IV) ibuprofen market. For instance, in December 2020, US food and drug administration (FDA) announced the published list of NSAIDs available by prescription and over-the-counter (OTC). It includes, ibuprofen, naproxen, diclofenac, and celecoxib while Ibuprofen and naproxen are also available OTC at lower strengths.

In addition, the U.S. food and drug administration (FDA) approved intravenous (IV) ibuprofen injection for pediatric use at definite doses. The increase in use of ibuprofen injection in children boosts the demand for intravenous (IV) ibuprofen injections. Thus, increase in pediatric population drives the growth of the market. For instance, the State of Americas Children 2021, reported that almost 22% population in the U.S. were children.

Moreover, development in intravenous ibuprofen formulations in the global intravenous (IV) ibuprofen market are anticipated to contribute toward the growth of the market. For instance, in November 2021, Cumberland Pharmaceuticals, a global leader in developing, manufacturing, and marketing a broad range of innovative pharmaceutical products, announced the U.S. Food and Drug Administration (FDA) approval for its caldolor, which is an intravenous ibuprofen used for pre-operative administration. However, side effects associated with ibuprofen impede the growth of the market.

Global Intravenous (IV) Ibuprofen Market Segmentation

The intravenous IV ibuprofen market is segmented on the basis of indication, age group, and region. By indication, the market is categorized into pain/inflammatory and fever. Depending on age group, it is fragmented into pediatrics and adults.  By region, the market is analyzed across Australia, Canada, South Korea, China, U.S.

[AGEGROUPGRAPH]

Get more information on this report : Request Sample Pages

Segment Review

Depending on indication, the pain/inflammatory segment dominated the IV ibuprofen market in 2020, and this trend is expected to continue during the forecast period, owing to rise in prevalence of mucoskelatal diseases. However, the fever segment is expected to witness considerable growth during the forecast period, due to prevalence of inflammatory diseases.

[INDICATIONGRAPH]

Get more information on this report : Request Sample Pages

On the basis of age group, the adults segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in prevalence of rare diseases in adults and rise in sedentary lifestyle by adult. However, the pediatrics segment is expected to witness considerable growth during the forecast period, due to increase in pediatric population.

Depending on the region, U.S. garnered the major share in the intravenous (IV) ibuprofen market in 2020, and is expected to dominate the global market during the forecast period, owing to the rise in prevalence of bone cancer, presence of key players for development of IV ibuprofen medication, and well-established infrastructure in the region. China is expected to register the highest CAGR of 15.2% from 2021 to 2030, owing to increase in the number of hospitals, prevalence of cancer, and high pediatric population base.

[REGIONGRAPH]

Get more information on this report : Request Sample Pages

The key players operating in the global intravenous (IV) ibuprofen market include, AFT Pharmaceuticals, Cumberland Pharmaceuticals Inc., Dano Health Group, Grifol, Harbin Gloria Pharmaceuticals Co., Ltd, Hyloris Pharmaceuticals SA, Pharma Bavaria International, Recordati, SG pharma, and XGEN.

Key Benefits For Stakeholders

• The report provides an in-depth analysis of the global intravenous (IV) ibuprofen market size along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers intravenous (IV) ibuprofen market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
• A comprehensive analysis of the region assists to understand the regional market and facilitate strategic business planning and determine prevailing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global intravenous (IV) ibuprofen market growth.

 Key Market Segments

• By Indication
  • Pain/Inflammatory
  • Fever
• By Age Group
  • Pediatrics
  • Adults
• By Region
  • U.S.
  • Australia
  • Canada
  • South Korea
  • China
• By Key Market Players
  • AFT Pharmaceuticals
  • Cumberland Pharmaceuticals Inc.
  • Dano Health Group
  • Grifol
  • Harbin Gloria Pharmaceuticals Co., Ltd
  • Hyloris Pharmaceuticals SA
  • Pharma Bavaria International
  • Recordati
  • SG pharma
  • XGEN

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics

3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: INTRAVENOUS (IV) IBUPROFEN MARKET, BY AGE GROUP

4.1 Overview

4.1.1 Market size and forecast

4.2 Pediatrics

4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country

4.3 Adults

4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country

CHAPTER 5: INTRAVENOUS (IV) IBUPROFEN MARKET, BY INDICATION

5.1 Overview

5.1.1 Market size and forecast

5.2 Fever

5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country

5.3 Pain

5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country

CHAPTER 6: INTRAVENOUS (IV) IBUPROFEN MARKET, BY COUNTRY

6.1 Overview

6.1.1 Market size and forecast

6.2 U.S.

6.2.1 Key trends and opportunities
6.2.2 U.S. Market size and forecast, by Age Group
6.2.3 U.S. Market size and forecast, by Indication

6.3 Australia

6.3.1 Key trends and opportunities
6.3.2 Australia Market size and forecast, by Age Group
6.3.3 Australia Market size and forecast, by Indication

6.4 Canada

6.4.1 Key trends and opportunities
6.4.2 Canada Market size and forecast, by Age Group
6.4.3 Canada Market size and forecast, by Indication

6.5 South Korea

6.5.1 Key trends and opportunities
6.5.2 South Korea Market size and forecast, by Age Group
6.5.3 South Korea Market size and forecast, by Indication

6.6 China

6.6.1 Key trends and opportunities
6.6.2 China Market size and forecast, by Age Group
6.6.3 China Market size and forecast, by Indication

CHAPTER 7: COMPANY LANDSCAPE

7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments

CHAPTER 8: COMPANY PROFILES

8.1 aft pharmaceuticals

8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments

8.2 Cumberland Pharmaceuticals Inc.

8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments

8.3 Dano Health Group

8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments

8.4 Grifols

8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments

8.5 Harbin Gloria Pharmaceuticals Co Ltd

8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments

8.6 Hyloris Pharmaceuticals SA

8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments

8.7 Pharma Bavaria International

8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments

8.8 recordati

8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments

8.9 SG pharma

8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments

8.10 XGEN

8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL INTRAVENOUS (IV) IBUPROFEN MARKET, BY AGE GROUP, 2020-2030,($MILLION)
TABLE 2. INTRAVENOUS (IV) IBUPROFEN MARKET REVENUE, FOR PEDIATRICS, BY REGION , 2020-2030,($MILLION)
TABLE 3. INTRAVENOUS (IV) IBUPROFEN MARKET PEDIATRICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. INTRAVENOUS (IV) IBUPROFEN MARKET REVENUE, FOR ADULTS, BY REGION , 2020-2030,($MILLION)
TABLE 5. INTRAVENOUS (IV) IBUPROFEN MARKET ADULTS BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. GLOBAL INTRAVENOUS (IV) IBUPROFEN MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 7. INTRAVENOUS (IV) IBUPROFEN MARKET REVENUE, FOR FEVER, BY REGION , 2020-2030,($MILLION)
TABLE 8. INTRAVENOUS (IV) IBUPROFEN MARKET FEVER BY COUNTRY, 2020-2030,($MILLION)
TABLE 9. INTRAVENOUS (IV) IBUPROFEN MARKET REVENUE, FOR PAIN, BY REGION , 2020-2030,($MILLION)
TABLE 10. INTRAVENOUS (IV) IBUPROFEN MARKET PAIN BY COUNTRY, 2020-2030,($MILLION)
TABLE 11. INTRAVENOUS (IV) IBUPROFEN MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 12. U.S. INTRAVENOUS (IV) IBUPROFEN MARKET, BY AGE GROUP, 2020-2030,($MILLION)
TABLE 13. U.S. INTRAVENOUS (IV) IBUPROFEN MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 14. AUSTRALIA INTRAVENOUS (IV) IBUPROFEN MARKET BY AGE GROUP 2020-2030,($MILLION)
TABLE 15. AUSTRALIA INTRAVENOUS (IV) IBUPROFEN MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 16. CANADA INTRAVENOUS (IV) IBUPROFEN MARKET BY AGE GROUP 2020-2030,($MILLION)
TABLE 17. CANADA INTRAVENOUS (IV) IBUPROFEN MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 18. SOUTH KOREA INTRAVENOUS (IV) IBUPROFEN MARKET, BY AGE GROUP, 2020-2030,($MILLION)
TABLE 19. SOUTH KOREA INTRAVENOUS (IV) IBUPROFEN MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 20. CHINA INTRAVENOUS (IV) IBUPROFEN MARKET BY AGE GROUP 2020-2030,($MILLION)
TABLE 21. CHINA INTRAVENOUS (IV) IBUPROFEN MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 22.AFT PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 23.AFT PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 24.AFT PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 25.AFT PHARMACEUTICALS: NET SALES,
TABLE 26.AFT PHARMACEUTICALS: KEY STRATERGIES
TABLE 27.CUMBERLAND PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 28.CUMBERLAND PHARMACEUTICALS INC.: OPERATING SEGMENTS
TABLE 29.CUMBERLAND PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 30.CUMBERLAND PHARMACEUTICALS INC.: NET SALES,
TABLE 31.CUMBERLAND PHARMACEUTICALS INC.: KEY STRATERGIES
TABLE 32.DANO HEALTH GROUP: COMPANY SNAPSHOT
TABLE 33.DANO HEALTH GROUP: OPERATING SEGMENTS
TABLE 34.DANO HEALTH GROUP: PRODUCT PORTFOLIO
TABLE 35.DANO HEALTH GROUP: NET SALES,
TABLE 36.DANO HEALTH GROUP: KEY STRATERGIES
TABLE 37.GRIFOLS: COMPANY SNAPSHOT
TABLE 38.GRIFOLS: OPERATING SEGMENTS
TABLE 39.GRIFOLS: PRODUCT PORTFOLIO
TABLE 40.GRIFOLS: NET SALES,
TABLE 41.GRIFOLS: KEY STRATERGIES
TABLE 42.HARBIN GLORIA PHARMACEUTICALS CO LTD: COMPANY SNAPSHOT
TABLE 43.HARBIN GLORIA PHARMACEUTICALS CO LTD: OPERATING SEGMENTS
TABLE 44.HARBIN GLORIA PHARMACEUTICALS CO LTD: PRODUCT PORTFOLIO
TABLE 45.HARBIN GLORIA PHARMACEUTICALS CO LTD: NET SALES,
TABLE 46.HARBIN GLORIA PHARMACEUTICALS CO LTD: KEY STRATERGIES
TABLE 47.HYLORIS PHARMACEUTICALS SA: COMPANY SNAPSHOT
TABLE 48.HYLORIS PHARMACEUTICALS SA: OPERATING SEGMENTS
TABLE 49.HYLORIS PHARMACEUTICALS SA: PRODUCT PORTFOLIO
TABLE 50.HYLORIS PHARMACEUTICALS SA: NET SALES,
TABLE 51.HYLORIS PHARMACEUTICALS SA: KEY STRATERGIES
TABLE 52.PHARMA BAVARIA INTERNATIONAL: COMPANY SNAPSHOT
TABLE 53.PHARMA BAVARIA INTERNATIONAL: OPERATING SEGMENTS
TABLE 54.PHARMA BAVARIA INTERNATIONAL: PRODUCT PORTFOLIO
TABLE 55.PHARMA BAVARIA INTERNATIONAL: NET SALES,
TABLE 56.PHARMA BAVARIA INTERNATIONAL: KEY STRATERGIES
TABLE 57.RECORDATI: COMPANY SNAPSHOT
TABLE 58.RECORDATI: OPERATING SEGMENTS
TABLE 59.RECORDATI: PRODUCT PORTFOLIO
TABLE 60.RECORDATI: NET SALES,
TABLE 61.RECORDATI: KEY STRATERGIES
TABLE 62.SG PHARMA: COMPANY SNAPSHOT
TABLE 63.SG PHARMA: OPERATING SEGMENTS
TABLE 64.SG PHARMA: PRODUCT PORTFOLIO
TABLE 65.SG PHARMA: NET SALES,
TABLE 66.SG PHARMA: KEY STRATERGIES
TABLE 67.XGEN: COMPANY SNAPSHOT
TABLE 68.XGEN: OPERATING SEGMENTS
TABLE 69.XGEN: PRODUCT PORTFOLIO
TABLE 70.XGEN: NET SALES,
TABLE 71.XGEN: KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.INTRAVENOUS (IV) IBUPROFEN MARKET SEGMENTATION
FIGURE 2.INTRAVENOUS (IV) IBUPROFEN MARKET,2020-2030
FIGURE 3.INTRAVENOUS (IV) IBUPROFEN MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.INTRAVENOUS (IV) IBUPROFEN MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11.INTRAVENOUS (IV) IBUPROFEN MARKET,BY AGE GROUP,2020(%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF PEDIATRICS INTRAVENOUS (IV) IBUPROFEN MARKET,2020-2030(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ADULTS INTRAVENOUS (IV) IBUPROFEN MARKET,2020-2030(%)
FIGURE 14.INTRAVENOUS (IV) IBUPROFEN MARKET,BY INDICATION,2020(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF FEVER INTRAVENOUS (IV) IBUPROFEN MARKET,2020-2030(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF PAIN INTRAVENOUS (IV) IBUPROFEN MARKET,2020-2030(%)
FIGURE 17.INTRAVENOUS (IV) IBUPROFEN MARKET BY COUNTRY,2020
FIGURE 18. TOP WINNING STRATEGIES, BY YEAR
FIGURE 19. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 20. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 21.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 22.COMPETITIVE DASHBOARD
FIGURE 23.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 24.AFT PHARMACEUTICALS.: NET SALES ,($MILLION)
FIGURE 25.CUMBERLAND PHARMACEUTICALS INC..: NET SALES ,($MILLION)
FIGURE 26.DANO HEALTH GROUP.: NET SALES ,($MILLION)
FIGURE 27.GRIFOLS.: NET SALES ,($MILLION)
FIGURE 28.HARBIN GLORIA PHARMACEUTICALS CO LTD.: NET SALES ,($MILLION)
FIGURE 29.HYLORIS PHARMACEUTICALS SA.: NET SALES ,($MILLION)
FIGURE 30.PHARMA BAVARIA INTERNATIONAL.: NET SALES ,($MILLION)
FIGURE 31.RECORDATI.: NET SALES ,($MILLION)
FIGURE 32.SG PHARMA.: NET SALES ,($MILLION)
FIGURE 33.XGEN.: NET SALES ,($MILLION)